Regeneron Pharmaceuticals' latest quarterly filing reveals a growing reliance on EYLEA HD to counterbalance declining sales of EYLEA due to increased biosimilar competition. Dupixent remains a critical revenue driver alongside a broad clinical pipeline supporting future growth. However, manufacturing capacity constraints and regulatory uncertainties pose risks. Collaborative partnerships with Sanofi and Bayer remain central to global commercialization efforts. The company’s substantial liquidity and investment in R&D underpin its integrated biotech platform, though market exclusivity challenges require close monitoring.